Poseida appoints new chief medical officer for CAR-T work

26 March 2024
biotech-appt

Poseida Therapeutics (Nasdaq: PSTX) has appointed Syed Rizvi as chief medical officer.

Dr Rizvi brings over 20 years of experience across all stages of drug development to the role, including most recently as CMO at Caribou Biosciences (Nasdaq: CRBU).

Prior to this, he held the same role at Chimeric Therapeutics, where he helped build the pipeline in part by licensing programs from universities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology